BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Diosynth Biotechnology (Research Triangle Park) Announces Amendment To Validation And Manufacturing Agreement With NeoPharm (NEOL) For IL13-PE38QQR


10/19/2005 5:12:28 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Sept. 21, 2005--Diosynth Biotechnology today announced that it has agreed to an amendment of the current agreement it has with NeoPharm, Inc. (NASDAQ: NEOL) to provide for Diosynth's performing validation and conformance lot manufacturing of NeoPharm's cintredekin besudotox (IL13-PE38QQR) drug candidate in the event NeoPharm is able to move forward with a Biologic License Application (BLA) at the conclusion of its pivotal Phase III PRECISE trial for cintredekin besudotox. Frank Tielens, Diosynth Biotechnology's President, expressed his gratitude to NeoPharm "for the continued trust shown in us as their contract manufacturer. This decision was supported by our successful track record producing IL 13-PE38QQR for use in their Phase I/II and Phase III "PRECISE" clinical trial for the treatment of glioblastoma multiforme." Further, Mr. Tielens indicated that Diosynth Biotechnology will use its expertise in process and analytical methods development for the validation of this biotechnology process.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES